IIL pursues not only the mandate of NDDB to provide products and services to enhance the quality of livestock in the country but also use its technological capabilities to the benefit of the people of India. IIL strongly believes that its mission of “Biotechnology in healthcare made affordable and accessible” can be actively pursued only with a sound technology base in modern biotechnology. IIL operates a facility in Ooty to manufacture the Vero cell culture rabies vaccine for use in human beings. This plant was set up in 1998 at the specific request of the Government of India so that the country can phase out use of the older and unsafe sheep brain vaccine (also termed nerve tissue vaccine – NTV) with the modern tissue culture vaccine. IIL sells the product under the brand name “Abhayrab” through its network of “Abhayclinics”.

IIL is the second company in the world to launch the purified Vero cell rabies vaccine (PVRV). The vaccine is sold at very economical price when compared to the brands of multinational companies. A new vaccine facility in Hyderabad has been setup to manufacture various other human vaccines such as Diphtheria, Pertussis, Tetanus, Recombinant Hepatitis B, Hepatitis A and Measles.

Achievements:

1983: Foot and Mouth Disease vaccine plant commissioned.
1985: Animal health products for the cooperative sector Introduced.
1989:

• First Indian company to manufacture tissue culture Veterinary Rabies vaccine.
• Tropical Theileriosis vaccine for cattle, first of its kind in the world.

1992:

• Introduction of Haemorrhagic Septicaemia (HS) and Black Quarter (BQ) Vaccines
• Introduction of Xylazine Hydrochloride injection, based on in-house research.

1996: Introduction of Enterotoxaemia vaccine.
1997: Awarded WHO GMP certification. Export avenues opened.
1998:

• Awarded ISO 9002 Certification.
• FMD – Ovac ((FMD adjuvant vaccine) introduced
• Vaccines for sheep and canines introduced.
• Human Rabies vaccine plant at Ooty commissioned.

1999:

• ‘Abhayrab’ introduced; Veterinary formulations range expanded.
• Abhay Clinics for mission of ‘Immunity made Affordable’.

2000: World ’s first combination vaccine for FMD, HS and BQ – Raksha Triovac.
2001:

• Unique medicated feed pellets – Vetfen-600 launched.
• Emerges as India ’s largest veterinary product exporter.

2002:

• Vaccine for Brucellosis in cattle launched.
• Human vaccine portfolio increased with Measles and MMR vaccine.
• Launched ‘Operation Pratirodh’ – Animal Health vaccination services.

2003:

• New Human Vaccines plant and Research and Development Center inaugurated.
• Introduction of unique concept of Fenbendazole through feed pellate.

2004:

• Nimovet-world’s first Nimesulide injection for livestock introduced.
• Indiagen Ltd, a company offering scientific &professional breeding services launched.
• IIL emerges as the fifth largest animal health company in India.
• Raksha FMD Vaccine emerges as the largest animal health brand in India.

2005: Abhayrig, an affordable immunoglobulin to treat class 3 dog bites introduced.
2006:

• Launch of the first vaccine from the Human Vaccine Manufacturing Plant Hyderabad – Elovac-B (r-DNA Hepatitis-B vaccine).
• 4th largest company in domestic animal health market
• Achieved milestone of Rs.100 Crores sales turnover
• Indian Immunologicals Ltd. wins the first ‘Corporate social responsibility’ award instituted by Animal Pharm

2007

• Launch of indigenously produced Measles Vaccine
• Launch of Raksha-PPR (Pestis des petits Ruminants) vaccine
• Launch of Animal Nutrition Division – Calsagar, Goumix, Goumin.
• IIL’s sales turnover reached Rs.158 Crores in 2006-07.

Corporate Office:

Indian Immunologicals Ltd.
Road # 44,
Jubilee Hills,
Hyderabad – 500 033
India.

Tel: +91-40-23544585/+91-40-23544593/+91-9948298322/+91-9948298422
Fax: +91-40-23544007

List of Offices

http://www.indimmune.com

Join the forum discussion on this post

The Serum Institute of India was founded by Cyrus Poonawalla and his brother Zavary in 1966 with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps and Rubella) group of vaccines. Poonawalla sold horses to raise the initial $12,000 needed to start the company. Using the money and a 12-acre (49,000 m2) lot used to bury horses, the brothers founded the company. Because they had no science background, they hired 10 doctors and scientists from the Haffkine Institute of India. After a number of legal hurdles, the company finally received permission to produce vaccines. Sales finally began picking up when the company won contracts to supply state governments and hospitals. Today, 80% of Serum’s sales are to groups Unicef and the Pan-American Health Organization as well as immunization programs like charity for children’s welfare in India, Germany, the majority of which are from developing markets. Serum became accredited by the World Health Organization in 1994, after which it began exporting vaccines from India. The company plans to enter to the western markets soon, in order to boost its revenue, through a partnership with American firm Akorn

The Philanthropic philosophy of the company still not only exists but has been proliferated to bring down the prices of newer vaccines such as Hepatitis-B vaccine, Rabies vaccine, Combination vaccine etc., so that not only Indian’s, but the entire under-privileged children of the world, in more than 140 countries are protected from birth onwards.

Serum Institute of India has set up Serum Bio Pharma Park, India’s first biotech Special Economic Zone (SEZ). The Park is adjoining Serum Institute’s existing manufacturing unit and is a sector-specific SEZ meant for biotechnology and pharmaceutical products. The SEZ will allow Serum Institute of India to avail various tax benefits such as income tax, import duty on capital goods etc. This has encouraged a lot of foreign companies to partner with Serum Institute of India to avail and share these benefits.

Milestones:

1967: Operations started with manufacture of Tetanus Antitoxin followed by Fluid Tetanus Toxoid.
1972: Large-scale manufacture of Adsorbed Tetanus Toxoid undertaken.
1974: Triple Antigen (Diphtheria-Tetanus-Pertussis) Vaccine production commenced.
1977: Autonomous scientific wing, Serum Institute of India Research Foundation established.
1979: In response to urgent requirement of vaccines for India’s EPI, giant Blending Vessels indigenously fabricated.
1980: First-time-in the-world collection of equine serum by simultaneous and continuous plasmapheresis using IBM Computerised Cell Separator.
1981: Manufacturing of life-saving Polyvalent Anti-Snake Venom Serum effective against four poisonous snakes commonly encountered in India commenced.
1982: Introduction of Anti-D Rho Immunoglobulin, Iyophilised and tested on Autoanalyser.
1984: A 2500- litre Blending Vessel, largest in the world for DTP vaccine, successfully fabricated and commissioned.
1984: Landmark visit, for technical conference, by Dr. Jonas Salk of Salk’s Polio Vaccine fame.
1985: Hi-tech plant set up for large-scale manufacture of Human Albumin from human placenta.
1986: The film ‘Snakebite’ awarded ‘Best Professional Film Award’ at ninth International Film Festival in U.S.A. Followed by two more international awards in 1987 and 1989.
1986: Technological breakthrough results in first-time-ever manufacture of Quadruple Vaccine (DTP with Inactivated Polio Vaccine).
1988: Product availability expanded to include range of Fertility Products of World Leaders, Serono of Switzerland.
1989: Manufacture of M-Vac (Measles Vaccine) using E-Z Strain of virus on Human Diploid Cells for the first time in India.
1991: Anti-snake Venom Serum, incorporating venoms from snakes in Central African Countries introduced.
1992: Manufacture of Rubella virus vaccine (monovalent Rubella vaccine) for the first time in India.
1993: Manufacture of MMR Vaccine and MR vaccine for the first time in India.
1993: Launch of Serum International Limited.
1994: Commencement of export of vaccines to UN agencies.
1996: Use of Automatic printing and Labelling Machine, use of Automatic Inspection Machine (screening) for liquids in ampoules and vials.
1997: Commencement of export of Anti-cancer products.
1997: Use of Modular Laboratory meeting international GMP requirements.
1998: Export of vaccines crossed over to 100 countries.
1999: Serum Institute recognised as the largest producer of Measles and DTP vaccines in the world.
2000: One out of every two children in the world vaccinated by Serum Institute’s vaccine.
2001: Launch of indigenously manufactured Recombinant Hepatitis-B vaccine ‘GeneVac-B’.
2002: Launch of BCG vaccine.
2004: Launched the World’s only adsorbed liquid HDC Rabies vaccine, SII RABIVAX.
2005: Launched indigenously developed DTP-HB Combination vaccine, SII Q-VAC.
2006: Launch of DTP-HB-HIB Vaccine
2007: Launch of Penta Vaccine

Rewards & Recognitions:

• Certificate of Merit awarded by CHEMEXCIL, Mumbai, for outstanding export performance in 1994-95.
• First Award under the Drugs and Pharmaceuticals panel from CHEMEXCIL, Mumbai, for sterling export performance in 1995-96.
• Certificate for Export Recognition (1st Rank) under the Export House category, from the Government of Maharashtra for export achievement in 1996-97.
• Vikas Bharati Award received in 1997 from International Council for Business Promotion, New Delhi, for outstanding achievements and contribution in the chosen field of activities, towards promotion and maintaining quality and standard of products/ services through innovative strategies.
• Certificate of Merit awarded by the Government of India, Ministry of Commerce for outstanding export performance in 1996-97.
• Export Excellence Award for 1996-97 and 1997-98 awarded to TOP TEN EXPORTERS from Pune Region by the Joint Director General of Foreign Trade, Pune and Mahratta Chamber of Commerce, Industries and Agriculture

Corporate Office:

Serum Institute of India Ltd.
212/2, Hadapsar,
Off Soli Poonawalla Road,
Pune – 411 028.
India

Tel: +91-20-26993900
Fax: +91-20-26993921

List of branch offices

http://www.seruminstitute.com/

Biocon Limited and its two subsidiary companies, Syngene International Limited and Clinigene International Limited form a fully integrated biotechnology enterprise specializing in biopharmaceuticals, custom research and clinical research. Biocon’s integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings and customised, high value solutions at any stage in the lifecycle of a drug-from discovery to market. Biocon’s vision is to be an integrated biopharmaceutical enterprise of global distinction.

The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments. Biocon’s products in the biopharmaceutical category include: anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, biologicals, cholesterol-lowering agents, haemostatic agents, hepatoprotective agents,
immunosuppressants, nutraceuticals and orthopaedic agents.

With its strong focus on R&D Biocon offers services in custom research (Syngene) in the fields of synthetic chemistry and molecular biology in early stage drug discovery and development. Clinical research (Clinigene) is carried out in the fields of clinical studies and clinical trials.

Biocon Park, inaugurated in June 2006 by President APJ Abdul Kalam comprises an integrated cluster of research laboratories and manufacturing facilities laid out on a 90 acre expanse in Bommasandra Industrial Area – Phase IV. Built with a total investment of Rs. 650 crores, with further investments to follow, Biocon Park is the single largest capital investment made by Biocon in its 32-year history and is focused on exports of both bio-pharmaceutical products and research services. The multi-product facilities mainly cater to the following disease segments: cardiovascular, cholesterol reduction, immunosuppressants in organ transplantation, diabetes and cancer.

Biocon’s success has been characterized by an enduring set of corporate values based on innovation, integrity, strong leadership and social responsibility. As India’s first and leading biotechnology company Biocon extends its support to numerous community outreach and corporate citizenship initiatives with special concentration in the areas of healthcare, education and environment. The Biocon Foundation, set up in 2004 has launched Arogya Raksha Yojana, a unique health initiative for rural India.

Biocon aims to continuously create growth in different areas of the company and is the first company, globally to manufacture human insulin, Insugen® using a Pichia expression system. In addition, in 2006, Biocon launched BIOMAb EGFR™, the first indigenously developed humanized monoclonal antibody for Head & Neck cancer.

Key Facts:

• Biocon is India’s first biotechnology company, established in 1978
• Biocon is the country’s first biotechnology company to export microbial enzymes to USA and Europe
• Biocon is the first biotechnology company to receive ISO 9001 certification in India
• Syngene, a Biocon subsidiary, is the country’s first biotech custom research company in drug discovery
• Biocon is the first Indian company to be approved by US FDA for the manufacture of pplovastatin, a cholesterol-lowering molecule
• Biocon’s subsidiary, Clinigene, has India’s first CAP (College of American Pathologists) accredited clinical research laboratory
• Biocon is the first company to manufacture human insulin using a Pichia expression system

Businesses:

Syngene: Pre-Clinical Discovery
Biocon’s custom research organisation, Syngene, offers high value discovery and development services, from target identification and validation to small molecule and library synthesis. With our reputation for meticulous IPR protection, we provide pharmaceutical and biotechnology majors customised solutions in the areas of synthetic chemistry and molecular biology.

Clinigene: Clinical Development
Biocon’s clinical research organisation, Clinigene, specialises in Phase I-IV clinical trials and studies, using well-characterised clinical databases in diabetes, oncology, lipidemia and cardiovascular diseases. We offer these services at our CAP and NABL accredited Central Reference Laboratory and a state-of-the-art Bioavailability and Bioequivalence (BA/BE) Centre.

Biocon: Commercialisation
Biocon has an impressive track record of commercialisation capabilities. We have brought to market a considerable portfolio of biopharmaceuticals, led by our blockbuster Statins. The commercialisation of Insulin, Immunossuppressants and a range of Biogenerics demonstrates our highly advanced process development and manufacturing expertise. Under rapid progress are two challenging collaborative projects for the development of novel medicine, including Oral Insulin and T1h. Biocon also markets a basket of branded formulations in India, among them INSUGEN®, BIOMAb EGFR® and EPO.

Milestones

• Biocon is India’s first biotechnology company, established in 1978
• Biocon is India’s first biotechnology company to export microbial enzymes to USA and Europe
• Biocon is the first biotechnology company to receive ISO 9001 certification in India
• Syngene, a Biocon subsidiary, is India’s first custom research company in drug discovery
• Biocon is the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule
• Biocon’s proprietary bioreactor, the PlaFractor™, receives a US patent
• Biocon’s subsidiary, Clinigene, has India’s first CAP (College of American Pathologists) accredited clinical research laboratory, setting the benchmark for laboratories in India
• Biocon is awarded the Biotech Product and Process Development and Commercialisation Award, 2001 by the Department of Biotechnology, Ministry of Science and Technology, Government of India
• Syngene is awarded the Certificate of Excellence for Export Achievement by the Government of India, for two consecutive years 2002-2003
• Biocon is the first company, globally to manufacture human insulin, INSUGEN®, using a Pichia expression system (2004)
• Biocon launches BIOMAb EGFR® India’s first anti-cancer, therapeutic Monoclonal Antibody-based drug for treating solid tumors of epithelial origin, such as head & neck cancers (2006)
• Biocon divests its enzymes division to Novozymes, focuses on biopharmaceuticals (2007)
• Syngene receives “BioServices Company of the Year”, BioSpectrum Awards (2007)
• Biocon’s BIOMAb EGFR® wins “Product of the Year”, BioSpectrum Awards (2007)
• Biocon acquires a 78% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million (2008)
• Biocon launches a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte- colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. ERYPRO Safe™ and NUFIL Safe™ are the first two drugs that will marketed using this novel device with other injectable products to follow in the future (2008)
• Biocon and Abraxis Bioscience launch ABRAXANE in India for treatment of Breast Cancer (2008)
• Biocon is ranked among the top 20 global biotechnology companies (Med Ad News) (2008)
• Biocon is the 7th largest biotech employer in the world (Med Ad News), 2008
• Biocon announced the results of an ascending dose study on its oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome (2008)
• NeoBiocon and Abraxis Bioscience launch Abraxane in The UAE for the treatment of Breast Cancer (2008)
• Biocon’s Syngene partners with Sapient Discovery to expand integrated drug discovery offerings (2009)
• Biocon’s Syngene and DuPont Crop Protection Forge Alliance Partnership (2009)
• Bristol-Myers Squibb and Biocon’s Syngene open new R&D Facility at Biocon Park (2009)
• Biocon launches BASALOG – long lasting basal insulin for Type 1 & Type 2 Diabetics (2009)
• Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management (2009)
• Biocon Announces Strategic Collaboration with Mylan to enter the Global Generic Biologics Market (2009)

Products:

Biopharmaceuticals

Active Pharmaceutical Ingredients (APIs)

• Anti-Diabetic Agents
• Anti-Inflammatory Agents
• Anti-Oxidants
• Cardiovascular Agents
• Anti-Obesity Agents
• Digestive-Aid Enzymes
• Anti-Hypertensive Agents
• Haemostatic Agents
• Hepatoprotective Agents
• Immunosuppressants
• Gastro-Intestinal Agents
• Nutraceuticals

Biologicals

• Insulin
• Streptokinase
• EPO
• GCSF
• Monoclonal Antibodies

Branded Formulations

Oncology

• BIOMAb EGFR®
• NUFIL safe™ (Pre-filled Syringe)
• NUFIL™ (Vials)
• Abraxane® for injectable suspension

Nephrology

• ERYPRO safe™ (Pre-filled Syringe)
• TACROGRAF™
• RAPACAN™
• CYCLOPHIL ME™
• RENODAPT®
• RENODAPT® – S
• CeRACaL™

Cardiology

• STATIX®
• STATIX®-F
• STATIX®-EZ
• BESTOR®
• TELMISAT™
• TELMISAT™-H
• ZARGO®
• ZARGO®-H
• ZIGPRIL®
• ACTIBLOK™-IPR
• BRADIA™
• CLASPRIN®
• THINRIN™
• MYOKINASE™
• CLOTIDE™
• DYNALIX®

Diabetology

• INSUGEN®-R
• INSUGEN®-N
• INSUGEN®-30/70
• INSUGEN®-50/50
• BASALOG™ 3ml, 10 ml
• BLISTO™ 1, 2 & 4
• BLISTO™-MF 1, 2 & 4
• METADOZE-IPR® 500 & 850
• PIODART®
• PIODART®-MF
• TriGPM™
• ZUKER™-MF
• GABIL™
• GMAB™ Plus
• OLISAT™

Corporate Headquarters:

20th KM Hosur Road
Electronics City
Bangalore – 560 100
India

Tel: +91-80-28082808/+91-80-40144014
Fax: +91-80-28523423

List of Offices

http://www.biocon.com

The company, through Dabur Pharma Ltd. does toxicology tests and markets ayurvedic medicines in a scientific manner. They have researched new medicines which will find use in O.T. all over the country therein opening a new market.

Dabur Foods, a subsidiary of Dabur India is expecting to grow at 25%. Its brands of juices, namely, Real and Active, together make it the market leader in the Fruit Juice Category.

Dabur is the co-owner of the IPL team Kings XI Punjab.

Key Facts:

Milestones:

IT Initiatives

• Migration from Baan and Mfg ERP Systems to centralized SAP ERP system from 1st April 2006 for all business units.
• Implementation of a country wide new WAN Infrastructure for running centralized ERP system.
• Setting up of new Data Centre at KCO Head Office.
• Extension of Reach System to distributors for capturing Secondary Sales Data.
• Roll out of IT services to new plants and CFAs.

• Upcoming Challenges
  • Forward Integration of SAP with Distributors and Stockists.
  • Backward Integration of SAP with Suppliers.
  • Implementation of new POS system at Stockist point and integration with SAP-ERP.
  • Implementation of SAP HR and payroll.
  • SAP Roll-out to DNPL and other new businesses.

Registered Office:

Corporate Office:

List of offices

http://www.dabur.com

By 2007, Cipla became the world’s largest manufacturer of antiretroviral drugs (ARVs) to fight HIV/AIDS, as measured by units produced and distributed (multinational brand-name drugs are much more expensive, so in money terms Cipla medicines are probably somewhere down the list). Roughly 40% of HIV/AIDS patients undergoing antiretroviral therapy worldwide take Cipla drugs. The company is ranked third in Generic market share statistics in South African Private Sector.

Because Indian law from 1972 has allowed no (end-product) patents on drugs, and provided for compulsory licensing, Cipla was able to manufacture medicines which enjoy patent monopoly in certain other countries (particularly those where large, multinational pharmaceutical companies are based). By doing so, as well as by making an executive decision not to make profits on AIDS medication, Cipla reduced the cost of providing antiretrovirals to AIDS patients from $12,000 and beyond (monopoly prices charged by international pharma conglomerates) down to around $300 per year. Today they are able to do so for under $150 per patient per year. While this sum remains out of reach for many millions of people in Third World countries, government and charitable sources often are in a position to make up the difference for destitute patients.

The customary treatment of AIDS consists of a cocktail of three drugs. Cipla produces an all-in-one pill called Triomune which contains all three substances (Lamivudine, stavudine and Nevirapine), something difficult elsewhere because the three patents are held by different companies. One more popular fixed dose combination is there, with the name Duovir-N. This contains Lamivudine, Zidovudine and Nevirapine.

Exports for the year 2008 amounted to more than Rs. 21,000 million. Cipla exports raw materials, intermediates, prescription drugs, OTC products and veterinary products. Cipla also offers technology for products and processes. Technical know-how/fees received during the year 2007-08 amounted to about Rs. 1500 million.

Cipla’s manufacturing facilities have been approved by the following regulatory authorities:

• Food and Drug Administration (FDA), USA
• Medicines and Healthcare products Regulatory Agency (MHRA), UK
• Therapeutic Goods Administration (TGA), Australia
• Medicines Control Council (MCC), South Africa
• National Institute of Pharmacy (NIP), Hungary
• Pharamaceutical Inspection Convention (PIC), Germany
• World Health Organisation (WHO) Department of Health, Canada
• State Institute for the Control of Drugs, Slovak Republic ANVISA, Brazil

Corporate office

Cipla Ltd.
Mumbai Central
Mumbai – 400 008
India

Tel: +91-22-23082891, 23095521
Fax: +91-22-23070013, 23070393

http://www.cipla.com

]]> http://www.provigator.com/cipla/feed 5 http://www.provigator.com/ranbaxy-laboratories-ltd http://www.provigator.com/ranbaxy-laboratories-ltd#comments Thu, 16 Apr 2009 02:40:22 +0000 admin http://www.provigator.com/?p=189 Ranbaxy Laboratories Limited is India’s largest pharmaceutical company. Incorporated in 1961, Ranbaxy exports its products to 125 countries with ground operations in 46 and manufacturing facilities in seven countries. It is ranked among the top 10 generic companies worldwide. Ranbaxy went public in 1973. Ranbaxy was started by Ranjit Singh and Gurbax Singh in 1937 as [...]]]> Ranbaxy Laboratories Limited is India’s largest pharmaceutical company. Incorporated in 1961, Ranbaxy exports its products to 125 countries with ground operations in 46 and manufacturing facilities in seven countries. It is ranked among the top 10 generic companies worldwide. Ranbaxy went public in 1973.

Ranbaxy was started by Ranjit Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi. Interestingly the name Ranbaxy is a portmanteau word from the names of its first owners Ranjit and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranjit Singh and Gurbax Singh. After Bhai Mohan Singh’s son Parvinder Singh joined the company in 1967, the company saw a significant transformation in its business and scale. His sons Malvinder Mohan Singh and Shivinder Mohan Singh sold the company to the Japanese company Daichi in June 2008.

Ranbaxy is one of the leading pharma Companies in India commanding a market share of 5.07%. (Source : ORG-IMS, March, 2007). The Company has clocked sales of USD 286 Mn (2006) registering a growth of over 17%. Growing ahead of the market the Company has enhanced its competitive position in the domestic market through its focused approach. The Company’s business has been realigned to its customer groups and investments have been made in high growth segments. These efforts have resulted in strengthening its Chronic franchise (Life Style led) as well as has reinforced its leading position in the Acute segment.
In the NDDS segment, Ranbaxy is the market leader with 7.9% market share and its NDDS product portfolio contributes to about 9% of its total turnover. Its product portfolio spans across Acute & Chronic Business covering Anti-infectives, Nutritionals, Gastro-intestinals, Pain Management ( Acute) Cardiovasculars, Dermatologicals, Central Nervous Systems (Chronic)segments.

Company’s India operations are a dominant force in a number of participating therapeutic segments, for example Anti-infectives, Statins, Dermatology and Pain Management Operations are structured into 9 Strategic Business Units. A publicly listed company, Ranbaxy India is also a member of IPA (Indian Pharmaceutical Alliance) & OPPI (Organization of Pharmaceutical Producers of India).

Amongst the pharmaceutical companies in India, Ranbaxy has the largest R&D budget with an R&D spend of over US $ 100Mn. Ranbaxy is among the few Indian pharmaceutical companies in India to have initiated its research program in the late 70’s. To support its global ambition, a first of its kind world class R&D centre was commissioned in 1994. Today, the Company’s multi-disciplinary R&D centre at Gurgaon, in India, houses dedicated facilities for generics research and innovative research. The Company’s robust R&D environment for both drug discovery & development reflects the Company’s commitment to be a leader in the generics space and offer value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes.

The new drug research areas at Ranbaxy include anti-infectives, inflammatory / respiratory, metabolic diseases, oncology, urology and anti-malaria. Presently, the Company has 8-10 programs comprising one anti-malaria molecule in Phase-II clinical trials. The Company has two programs in Phase I and the remaining in the pre-clinical stage. This includes a collaborative research program with GSK.

The company’s NDDS focus is mainly on the development of NDA/ANDAs of oral controlled- release products for the regulated markets. The Company’s first significant international success using the NDDS technology platform came in September 1999, when Ranbaxy out-licensed its first once-a-day formulation to a multinational company.

Corporate Office:

Ranbaxy Laboratories Limited
Corporate Office
Plot 90, Sector 32,
Gurgaon – 122001
Haryana.
India

Tel: +91-124-4135000
Fax: +91-124-4135001

List of offices

http://www.ranbaxy.com

Established in 1983, Sun Pharma was a start-up company with five products. Since 1996, Sun has grown largely through a combination of internal growth, and acquisition of other pharmaceutical companies. Important mergers includes those of the US, Detroit based Caraco Pharm Labs, ICN Hungary (now called Alkaloida Chemical Company Exclusive Group), and that of the internationally approved plants at Halol, India as well as Bryan, Ohio, US and Cranbury, NJ, US.

A planned acquisition of Israeli Taro Pharmaceuticals initiated in March 2007 was terminated by the Taro board in May 2008.
As of 2008, it has grown to become an international speciality pharma company with more than 7000 employees, 17 manufacturing locations worldwide, two research centers, and a presence in 30 countries. It is one of the leading Indian-based pharma companies in India.

Corporate Office:

Sun Pharma
Acme Plaza,
Andheri – Kurla Rd,
Andheri (E),
Mumbai – 400 059.
India

List of offices

http://www.sunpharma.com

The company has contributed significantly to the medical fraternity through presence in important therapeutic areas like Pain Management, Anti Diabetics, Anti Osteoporotics, Renal Transplantation Drugs, Immunoglobulins, Cardiac Emergency Drugs, Antibiotics etc. Presently, the Company generates an annual revenue of $ 200 million.

Panacea Biotec has engineered its sales and marketing network for pharmaceutical formulations into strategic business units (SBUs), which comprise Critical Care, Diacar, Procare and Growcare. The company has launched a new SBU, viz. Oncotrust.
The aim of each SBU is to attain leadership position in its respective markets and establish brand equity in respective therapeutic segment by implementing the concept of Customer Relationship Management (CRM) for better coverage and servicing of customers. The SBUs promote a portfolio of brands with a special focus on Orthopedicians, Cardiologists, Diabetologists, Physicians, Nephrologists, Pulmonologists, Surgeons, Dentists, ENT (Ear, Nose and Throat) specialists, Pediatricians and Gastro-enterologists.

Critical Care
Critical Care, a Super Speciality SBU of the company, is focused on Nephrology therapy in the highly specialized organ transplantation and dialysis management segments. It offers a complete range of pre-transplant & post-transplant therapies. The SBU has carved a niche in super-specialty segment and created a scientific image. The SBU is rightly poised for achieving clear leadership in the Nephrology & Transplantation segment.

Diacar
Diacar is the highest contributing SBU of the company with dedicated marketing and sales infrastructure for Diabetes and Cardiovascular management. Diacar SBU is valued at Rs.460 million (ORG IMS Mar’07 MAT). The SBU promotes the brands to the target specialists viz. Endocrinologists, Diabetologists and Physicians in a fiercely competitive scenario and has achieved significant leadership position in Oral anti-diabetic segment.

Procare
Procare SBU of the company endeavors to consolidate and strengthen its image in the field of chronic health care management with specific focus on pain and arthritis management, osteoporosis and gastrointestinal disorders. It promotes a portfolio of brands with special focus on Orthopedicians, Surgeons, Dentists, ENT specialist & Gastroenterologist apart from Consulting Physician and General Physician.

Growcare
Growcare is the respiratory and pediatric business of Panacea Biotec. This business was carved out of the existing business of Panacea Biotec as part of the long term strategy to enter the high growth Respiratory Therapy. Growcare is a Rs.230 million business with total field strength of around 350 people and services more than 50,000 doctors across the country, comprising of different specialties like Chest Physicians, Consulting Physicians, Pediatricians and General Physicians. 26 different SKUs are marketed with presence in multiple Therapy areas.

Oncotrust
Panacea Biotec has plans to foray into oncology segment to provide treatment for Cancer, viz, breast cancer, brain tumor, ovarian cancer, pancreatic cancer, prostrate cancer and colorectal cancer. ‘ Oncotrust’ is the new Strategic Business Unit (SBU) with the total strength of around 50 sales specialists on oncology who would be responsible for marketing these drugs.

Corporate Office:

Panacea Biotec Ltd.,
B-1 Extn./ A-27,
Mohan Co-op. Industrial Estate,
Mathura Road,
New Delhi – 110 044.
India.

Tel: +91-11-26945270, 26974500, 41678000
Fax: +91-11-41679081, 26940199

http://www.panacea-biotec.com

Dr. Reddy’s began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets – that had the advantage of not having to spend time and money on a manufacturing plant that that would gain approval from a drug licensing body such as the US’s Food and Drug Administration. Much of Reddy’s early success came in those unregulated markets, where process patents – not product patents – are recognized. With that money in the bank, the company could reverse-engineer patented drugs from more developed countries and sell them royalty-free in India and Russia. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.

The company has a presence across the value chain, producing and delivering safe, innovative, and high quality finished dosage forms, active pharmaceutical ingredients and biological products, which are marketed to over 100 countries including US, Europe, Russia, Asia Pacific, India and China.

The Company conducts NCE drug discovery research in the areas of metabolic disorders, cardiovascular indications and infectious diseases. Its drug discovery effort is carried out at its research facilities in Atlanta, USA, and in Hyderabad, India.

By 2007, Dr. Reddy’s had six FDA-plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications – five of them in India and two in the UK.

The company top 10 brands in the India market are:

Omez
Nise
Stamlo
Stamlo Beta
Enam
Atocor
Razo
Reclimet
Clamp
Mintop

Corporate Office:

Dr. Reddy’s Laboratories Ltd.
Greenlands,
Ameerpet,
Hyderabad – 500 016
India

Tel: +91-40-23731946 / 47 / 48 / 49 / 50
Fax: +91-40-23731955

List of office

http://www.drreddys.com